Novartis Receives European Approval for Onbrez for COPD

Thursday, Novartis AG ADS, a Swiss drug maker, said that the European Commission has approved its lead compound Onbrez Breezhaler in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease or COPD.
RTTNews